JP2010536365A - 前立腺癌の治療及び診断の標的遺伝子のための、ｐｋｉｂ及びｎａａｌａｄｌ２ - Google Patents

前立腺癌の治療及び診断の標的遺伝子のための、ｐｋｉｂ及びｎａａｌａｄｌ２ Download PDF

Info

Publication number
JP2010536365A
JP2010536365A JP2010521579A JP2010521579A JP2010536365A JP 2010536365 A JP2010536365 A JP 2010536365A JP 2010521579 A JP2010521579 A JP 2010521579A JP 2010521579 A JP2010521579 A JP 2010521579A JP 2010536365 A JP2010536365 A JP 2010536365A
Authority
JP
Japan
Prior art keywords
pkib
seq
double
naaladl2
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010521579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536365A5 (pt
Inventor
祐輔 中村
英刀 中川
修一 中鶴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2010536365A publication Critical patent/JP2010536365A/ja
Publication of JP2010536365A5 publication Critical patent/JP2010536365A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2010521579A 2007-08-24 2008-08-20 前立腺癌の治療及び診断の標的遺伝子のための、ｐｋｉｂ及びｎａａｌａｄｌ２ Withdrawn JP2010536365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95785307P 2007-08-24 2007-08-24
US3603008P 2008-03-12 2008-03-12
PCT/JP2008/065234 WO2009028521A1 (en) 2007-08-24 2008-08-20 Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis

Publications (2)

Publication Number Publication Date
JP2010536365A true JP2010536365A (ja) 2010-12-02
JP2010536365A5 JP2010536365A5 (pt) 2011-10-06

Family

ID=40387239

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521579A Withdrawn JP2010536365A (ja) 2007-08-24 2008-08-20 前立腺癌の治療及び診断の標的遺伝子のための、ｐｋｉｂ及びｎａａｌａｄｌ２

Country Status (10)

Country Link
US (1) US20120022128A1 (pt)
EP (1) EP2195425A4 (pt)
JP (1) JP2010536365A (pt)
KR (1) KR20100075452A (pt)
CN (1) CN101855346A (pt)
BR (1) BRPI0815757A2 (pt)
CA (1) CA2697512A1 (pt)
RU (1) RU2010111116A (pt)
TW (1) TW200920405A (pt)
WO (1) WO2009028521A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511767A (ja) * 2013-02-25 2016-04-21 オックスフォード ビオトヘラペウトイクス エルティーディー． 治療的及び診断的標的としての不活性Ｎ−アセチル化−α−結合型酸性ジペプチダーゼ−様タンパク質２（ＮＡＡＬＡＤＬ２）

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945848B2 (en) * 2009-07-31 2015-02-03 Chromocell Corporation Methods and compositions for identifying and validating modulators of cell fate
KR101164645B1 (ko) * 2011-10-07 2012-07-20 대한민국 Ｇｃｐⅱ 돌연변이를 함유하는 알츠하이머 예방 및 치료용 약학적 조성물
GB201304612D0 (en) * 2013-03-14 2013-05-01 Cancer Rec Tech Ltd Diagnostic and prognostic biomarkers for prostate cancer and other disorders
US11261495B2 (en) * 2014-01-03 2022-03-01 Koninklijke Philips N.V. Assessment of the PI3K cellular signaling pathway activity using mathematical modelling of target gene expression
KR101824303B1 (ko) 2015-08-06 2018-01-31 부경대학교 산학협력단 종이형 전립선암 진단센서, 이의 제조방법, 및 이를 이용한 전립선암 진단방법
CN114177296B (zh) * 2021-12-16 2023-05-26 上海交通大学医学院附属第九人民医院 Mpc的过表达或活性提高在制备预防和/或治疗前列腺癌的药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
AU2003282877B9 (en) 2002-09-25 2011-05-12 University Of Massachusetts In Vivo gene silencing by chemically modified and stable siRNA
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1636342A4 (en) 2003-06-20 2008-10-08 Isis Pharmaceuticals Inc OLIGOMERIC COMPOUNDS FOR GENE MODULATION
US20050136437A1 (en) 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2007525220A (ja) * 2004-02-27 2007-09-06 オンコセラピー・サイエンス株式会社 Ｐｉｎ−ｐｒｃ移行遺伝子
EP2343384A3 (en) * 2004-03-23 2012-01-04 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancer
WO2006026051A2 (en) * 2004-08-03 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis, prognosis and for targeting the therapy of neuroblastoma
WO2007013479A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
EP2311985A1 (en) * 2005-07-27 2011-04-20 Oncotherapy Science, Inc. Sirna for treating esophageal cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511767A (ja) * 2013-02-25 2016-04-21 オックスフォード ビオトヘラペウトイクス エルティーディー． 治療的及び診断的標的としての不活性Ｎ−アセチル化−α−結合型酸性ジペプチダーゼ−様タンパク質２（ＮＡＡＬＡＤＬ２）

Also Published As

Publication number Publication date
EP2195425A4 (en) 2011-01-19
CN101855346A (zh) 2010-10-06
WO2009028521A1 (en) 2009-03-05
KR20100075452A (ko) 2010-07-02
CA2697512A1 (en) 2009-03-05
BRPI0815757A2 (pt) 2015-02-18
RU2010111116A (ru) 2011-09-27
EP2195425A1 (en) 2010-06-16
TW200920405A (en) 2009-05-16
US20120022128A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
JP5764822B2 (ja) がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
WO2012144220A1 (en) Ezh2 as target gene for cancer therapy and diagnosis
WO2011096210A1 (en) Prmt1 and prmt6 for target genes of cancer therapy and diagnosis
JP2006517783A (ja) ヒト骨髄性白血病に関連する遺伝子およびポリペプチド
TW200920406A (en) EBI3, DLX5, NPTX1 and CDKN3 for target genes of lung cancer therapy and diagnosis
JP2013518560A (ja) がんの治療および診断の標的遺伝子としてのｗｈｓｃ１およびｗｈｓｃ１ｌ１
JP2012509058A (ja) 前立腺癌を診断または治療するための方法
JP2010536365A (ja) 前立腺癌の治療及び診断の標的遺伝子のための、ｐｋｉｂ及びｎａａｌａｄｌ２
JP2012501167A (ja) 膵臓癌関連遺伝子ｔｔｌｌ４
JP6064231B2 (ja) がん治療および診断のための標的遺伝子としてのｓｕｖ３９ｈ２
WO2012090479A1 (en) Mcm7 as a target gene for cancer therapy and diagnosis
WO2010023855A1 (en) C12orf48 as a target gene for cancer therapy and diagnosis
JP2012501161A (ja) 癌の治療および診断の標的遺伝子としてのｓｙｎｇｒ４
WO2009113295A1 (en) C2orf18 as target gene for cancer therapy and diagnosis
US20120022131A1 (en) Breast cancer related gene rqcd1
WO2011024433A1 (en) Lung and esophageal cancer related gene adamts18
JP2008505601A (ja) 前立腺癌に関連した遺伝子及びポリペプチド
WO2012023288A1 (en) Fam161a as a target gene for cancer therapy and diagnosis
WO2011021386A1 (en) Cstf2 for target genes of lung cancer therapy and diagnosis
JP2013538568A (ja) がんの治療および診断のための標的遺伝子としてのｓｕｖ４２０ｈ１およびｓｕｖ４２０ｈ２
JP2013502202A (ja) 乳癌関連遺伝子Ｃ１２ｏｒｆ３２
JP2013542711A (ja) がんの治療および診断の標的遺伝子としてのＣ６ｏｒｆ１６７
JP2013502901A (ja) がんの治療および診断の標的遺伝子としてのｅｒｃｃ６ｌ

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110818

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120706